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SHORT COMMUNICATION
Mental disorders and drug/alcohol use in patients commencing 
extensively drug-resistant tuberculosis treatment
J. Scuffell,1 D. Boccia,2 F. Garcia Velarde,3 S. R. Leon,3 G. Raviola,4 L. Lecca,3,4 J. T. Galea3,4
Adherence to antimicrobial regimens is critical for optimal tuberculosis (TB) treatment. Comor-
bid mental disorders, including depression, anxiety, 
psychosis and drug/alcohol use disorders—present in 
up to 70% of TB patients1—are associated with poorer 
outcomes.2 While some patients begin anti-tubercu-
losis treatment with pre-existing mental disorders, 
onset sometimes occurs due to added bio-psychoso-
cial stressors during TB treatment, psychiatric side-ef-
fects of anti-tuberculosis drugs or drug interactions 
between antimicrobial and antipsychotic medica-
tions.1,3 Particularly for patients with multi-drug re-
sistant (MDR) TB, where treatment can last for years, 
addressing comorbid mental disorders such as de-
pression increases cure rates and patient wellbeing.4 
A study from Peru was among the first to demon-
strate the benefit of psychosocial support for MDR-TB 
patients with mental disorders, reporting a TB treat-
ment non-completion rate of 3%.5 Nonetheless, inte-
grated TB and mental health services are not the 
global norm.3 Moreover, only scant data exist on the 
prevalence of mental health comorbidities among 
MDR-TB patients, and we are unaware of any pub-
lished data for extensively drug-resistant (XDR) TB, 
which requires longer, more toxic treatment 
regimens.
Peru, designated by the World Health Organization 
(WHO) as a high MDR-TB burden country, has an an-
nual MDR-TB incidence rate of 10 per 10 000 popula-
tion.6 This pilot study investigated the baseline preva-
lence of comorbid mental disorders and drug/alcohol 
use and their association with outcomes among a 
small sample of Peruvian XDR-TB patients.
ASPECT OF INTEREST
Methods
We conducted a retrospective case series analysing pa-
tients commencing their first XDR-TB treatment epi-
sode in Peru during 2010–2012. In accordance with 
Peru’s National TB Programme (NTP) recommenda-
tions, XDR-TB patients receive a baseline clinical as-
sessment from a psychologist or psychiatrist to screen 
for mental health conditions using the International 
Classification of Diseases 10th revision (ICD-10). De-
mographic and clinical data were abstracted from 
medical charts in the NTP’s central archive onto paper 
forms during June–July 2015. The data were then sin-
gle-entered and cleaned electronically using EpiData 
v3.1 (EpiData Association, Odense, Denmark), Excel 
2011 (Microsoft Corp, Redmond, USA) and q (Ben-At-
tia Harel, Israel).
The prevalence of mental disorders—depression, 
anxiety, mixed anxiety-depressive disorder and psy-
chosis—and alcohol and drug use was calculated. Us-
ing the Peruvian NTP definition for XDR-TB treat-
ment outcomes (Table 1), we estimated the crude 
odds ratios (OR) for unfavourable (failure, loss to fol-
low-up, death) outcomes for mental disorders and 
current drug/alcohol use using exact logistic regres-
sion using Stata 13.0 (StataCorp, College Station, 
TX, USA).
The study was approved by the Human Ethics Re-
search Committees at the Universidad Peruana Cay-
etano Heredia (Lima, Peru) and London School of Hy-
giene & Tropical Medicine (London, UK).
RESULTS
We abstracted treatment data for 53 XDR-TB patients 
who were mostly males aged 19–66 years living in 
metropolitan Lima/Callao. One patient was a second-
ary XDR-TB case, while the remainder had a median 
of 2.35 years of previous anti-tuberculosis treatment 
(interquartile range [IQR] 9.6 months–3.75 years). Of 
the 53 patients, 49 had documented psychiatric evalu-
ations, of whom 11/49 were diagnosed with a mental 
disorder: five with depression, three with anxiety, two 
with mixed anxiety-depressive disorder and one with 
psychosis. Overall treatment outcomes were: 12/49 fa-
vourable (seven cured, five completed) and 37/49 un-
favourable (11 lost to follow-up, 11 failures and 15 
deaths). Among those diagnosed with mental disor-
ders, 9/11 had an unfavourable treatment outcome. 
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Mental disorders and alcohol/drug use worsen treatment 
outcomes for multidrug-resistant tuberculosis (TB), but 
data are lacking for extensively drug-resistant (XDR) TB. 
We investigated the association of baseline mental disor-
ders and alcohol/drug use on XDR-TB treatment out-
comes in a retrospective study of 53 XDR-TB Peruvian 
patients during 2010–2012. Logistic regression estimated 
the odds ratios for unfavourable XDR-TB treatment out-
comes. Overall treatment success was 25%. Mental disor-
ders and drug/alcohol use were found in respectively 
22.4% and 20.4% of patients; neither were associated 
with unfavourable treatment outcomes. Future research 
should explore the relationship between mental health 
and drug/alcohol use in XDR-TB treatment outcomes.
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Three of the four patients without psychiatric assess-
ments had unfavourable outcomes (Table 2).
Regarding alcohol use, 8/49 patients were consum-
ing alcohol at baseline, of whom two were diagnosed 
with alcoholism. A further 11/49 had a history of alco-
hol consumption. Six patients currently used drugs; 
five more had a history of drug use. Nearly half (22/49) 
had a current or prior history of alcohol/drug use; 
these patients tended to have unfavourable outcomes.
There was no statistical evidence that a diagnosis of 
mental disorder (OR 1.59, 95% confidence interval 
[CI] 0.26–7.6, P = 0.70) or current alcohol/drug use 
(OR 0.71, 95%CI 0.12–5.09, P = 0.69) were associated 
with increased odds of worse XDR-TB treatment 
outcomes.
DISCUSSION
To our knowledge, this retrospective series is the first 
to report on XDR-TB psychiatric comorbidity in Peru 
or elsewhere. The point prevalences of baseline depres-
sion and anxiety observed in this cohort of XDR-TB 
patients were greater than for the adult population of 
Lima/Callao (10.2% vs. 2.8% and 6.1% vs. 1.9%, re-
spectively), while rates of psychosis and alcohol/drug 
use were comparable to the general population.7 Com-
pared to the first 75 MDR-TB patients in Peru to re-
ceive individualised therapy (1996–1999), depression 
was less prevalent in the present study (10.2% vs. 
52.2%), but the prevalence of anxiety was similar 
(6.1% vs. 8.7%).8 However, our results for all psychiat-
ric conditions are comparable to a larger MDR-TB co-
hort in Peru (22.4% vs. 18.9%).2 Nonetheless, we 
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TABLE 1 Definitions of XDR-TB treatment outcomes, 
Peru National Tuberculosis Programme
Outcome Definition
Cure Completion of at least 24 months of 
XDR-TB treatment, with 10 negative 
cultures in the final 12 months of 
treatment
Completion Completion of treatment on the 
advice of a physician, without other 
criteria to categorize the treatment 
as cure
Loss to follow-up Interruption of treatment for ≥30 days
Failure Failure to achieve sputum conversion 
by the 6th month of treatment (two 
consecutive cultures at least 30 days 
apart), or bacteriological reversion 
(two consecutive positive cultures at 
least 30 days apart) or amplification 
of resistance
Death Death from any cause during XDR-TB 
treatment
XDR-TB = extensively drug-resistant tuberculosis.
TABLE 2 Prevalence of psychiatric conditions at baseline among 49 patients commencing XDR-TB treatment in Peru, 2010–2012
(N = 49)
n
Prevalence
% (95%CI)
Unfavourable outcomes
n (%)
Unfavourable outcomes
Crude OR (95%CI) P value*
Sex
 Female 17 34.7 (22.4–49.4) 14 (82)
 Male 32 65.3 (50.6–77.6) 23 (72)
Age at initiation of XDR-TB treatment, years
 19–25 12 24.5 (14.2–38.9) 10 (83)
 26–40 21 42.9 (29.4–57.4) 15 (71)
 41–66 16 32.7 (20.7–47.4) 12 (75)
Mental disorder, alcohol or drug use
 Current 17 34.7 (22.4–49.4) 13 (76)
 Not current 32 65.3 (50.6–77.6) 24 (75)
Mental disorder 11 22.4 (12.6–36.7) 9 (82) 1.59 (0.26–17.6) 0.71
 Depression 5 10.2 (4.2–22.9) 4 (80)
 Anxiety 3 6.1 (1.9–18.0) 3 (100)
 Mixed anxiety-depressive disorder 2 4.1 (1.0–15.6) 2 (100)
 Psychosis 1 2.0 (0.2–14.0) 0
 No mental disorder 38 77.6 (63.3–87.4) 28 (74)
Alcohol and drug use 22 44.9 (31.3–59.4) 15 (68)
 Current All 10 20.4 (11.1–34.5) 7 (70) 0.71 (0.12–5.09) 0.69
Alcohol 8 16.3 (8.2–30.0) 6 (75)
 Alcoholism 2 4.1 (1.0–15.6) 2 (100)
Drugs† 6 12.2 (5.4–25.3) 4 (67)
 Past All 13 26.5 (15.8–41.1) 8 (62)
Alcohol 11 22.4 (12.6–36.7) 6 (55)
Drugs† 5 10.2 (4.2–22.9) 3 (60)
 No current alcohol or drug use 39 79.6 (65.5–88.9) 30 (77)
* Derived from conditional score tests.
† Marijuana, cocaine/cocaine precursor.
XDR-TB = extensively drug-resistant tuberculosis; CI = confidence interval; OR = odds ratio.
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found no association of psychiatric conditions or drug/alcohol 
use with unfavourable XDR-TB outcomes.
Prospective studies and qualitative inquiry would shed further 
light on these unexpected findings. It may be that patients with 
pre-existing (prior to XDR-TB treatment) mental disorders were 
less likely to present for care, or had died before they could, and 
were therefore underrepresented in our sample. Alternatively, pa-
tients may have been too gravely ill to be evaluated with appro-
priate instruments, thereby underestimating the true prevalence 
of psychiatric disorders. Patients who were not using alcohol/
drugs at baseline may have restarted once treatment improved 
their TB symptomatology. As it is unlikely that psychiatric disor-
ders are protective factors during XDR-TB treatment, NTPs should 
assume that mental health interventions would increase patient 
wellbeing and reduce loss to follow-up. Initiatives such as the 
WHO End TB strategy9 and Zero TB,10 which include mental 
health support as core components, offer promise; however, more 
data are needed on specific comorbid mental disorders with 
XDR-TB to develop the most successful interventions.
Due to the small sample size and missing data, such as pa-
tients’ socio-economic status and whether diagnoses were made 
by psychiatrists or psychologists, key confounders cannot be 
ruled out. As the mental health evaluations were performed at 
treatment initiation, we could not assess the incidence of mental 
disorders.
CONCLUSION
Baseline psychiatric disorders and drug/alcohol use were not asso-
ciated with poor XDR-TB outcomes; however, overall treatment 
success was low. Appropriately powered cohort studies are needed 
to better understand mental health issues affecting XDR-TB pa-
tients throughout treatment and develop interventions that im-
prove patients’ survival and quality of life.
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Les troubles mentaux et la consommation d’alcool/de drogue 
entravent le résultat du traitement de la tuberculose multirésistante 
(TB-MDR), mais on manque de données pour la TB ultrarésistante 
(TB-XDR). Nous avons examiné l’association de troubles mentaux 
préexistants et de consommation d’alcool/de drogue sur le résultat 
du traitement de la TB-XDR dans une étude rétrospective de 53 
patients péruviens atteints de TB-XDR en 2010–2012. Une régression 
logistique a estimé les odds ratios de résultat défavorable du 
traitement de la TB-XDR. Le taux d’ensemble de succès du traitement 
a été de 25%. Des troubles mentaux et une consommation d’alcool/
de drogue ont été constatés chez respectivement 22,4% et 20,4% 
des patients ; aucun n’a été associé à un résultat défavorable du 
traitement. Des recherches ultérieures devraient explorer la relation 
entre santé mentale et consommation de drogue/alcool et leur 
impact sur le traitement de la TB-XDR.  
Los trastornos mentales y el consumo de alcohol y de drogas agravan 
los desenlaces terapéuticos de la tuberculosis multidrogorresistente 
(TB-MDR), pero no existen datos en cuanto a la TB extremadamente 
resistente (TB-XDR). En un estudio retrospectivo en 53 pacientes 
peruianos que padecieron TB-XDR del 2010 al 2012, se investigó la 
asociación de la presencia inicial de trastornos mentales y consumo 
de alcohol o drogas con los desenlaces del tratamiento de la TB-XDR. 
Mediante un modelo de regresión logística se calcularon los cocientes 
de posibilidades de desenlaces terapéuticos desfavorables. La tasa 
global de éxito terapéutico fue de 25%. Se encontró que el 22,4% de 
los pacientes sufría trastornos mentales y el 20,4% consumía alcohol 
o drogas; ninguna de estas características se asoció con desenlaces 
desfavorables del tratamiento. Nuevas investigaciones tendrán que 
explorar la correlación que existe entre la salud mental y el consumo 
de alcohol o drogas y los desenlaces terapéuticos de la TB-XDR.  
